InnoCare Pharma Ltd
33C
Company Profile
Business description
InnoCare Pharma Ltd is a commercial-stage biopharmaceutical company. It discovers, develops, and commercializes drugs for the treatment of cancer and autoimmune diseases. The company's main product pipeline includes orelabrutinib, ibrutinib, zanubrutinib, tafasitamab, ICP-490, ICP-B02, ICP-248, ICP-192, ICP-723, and ICP-189, among others. Its products are mainly used to treat hematological tumors, solid tumors, and autoimmune diseases. The company is also developing products for the treatment of autoimmune diseases caused by abnormal B-cell or T-cell function.
Contact
No. 8 Life Science Park Road
Building 8, Zhongguancun Life Science Park
Changping District
Beijing102206
CHNT: +86 1066609999
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
1,176
Stocks News & Analysis
stocks
Apple: Gemini partnership lets AI-worried investors breathe a sigh of relief
We believe a competitive—if not leading—AI feature suite will reinforce Apple’s wide-moat mobile device ecosystem.
stocks
ASX share ticks all the popular thematic boxes
The shares are overvalued as investors are overly excited about defence and gold exposure.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,124.30 | 27.40 | -0.30% |
| CAC 40 | 8,347.20 | 0.00 | 0.00% |
| DAX 40 | 25,420.66 | 15.32 | 0.06% |
| Dow JONES (US) | 49,191.99 | 398.21 | -0.80% |
| FTSE 100 | 10,137.35 | 3.35 | -0.03% |
| HKSE | 27,037.79 | 189.32 | 0.71% |
| NASDAQ | 23,709.87 | 24.03 | -0.10% |
| Nikkei 225 | 54,413.92 | 864.76 | 1.61% |
| NZX 50 Index | 13,718.02 | 61.97 | 0.45% |
| S&P 500 | 6,963.74 | 13.53 | -0.19% |
| S&P/ASX 200 | 8,793.90 | 27.90 | -0.32% |
| SSE Composite Index | 4,179.40 | 40.65 | 0.98% |